发现树突状细胞疗法
基于树突细胞的免疫疗法于2010年在美国首次获批作为用于治疗前列腺癌的疫苗接种癌症疗法。从那时起,已经有超过4,500篇关于用这种癌症疫苗治疗的患者的研究发表。在研究中,已发现树突状细胞癌治疗可提供治疗性和保护性抗肿瘤免疫力。对患有黑色素瘤,神经胶质瘤和非霍奇金淋巴瘤的癌症患者的临床试验显示出令人鼓舞的抗肿瘤结果。
树突状细胞疫苗治疗的作用原理
树突状细胞疫苗治疗是一种独特的免疫疗法,在癌症患者中变得越来越重要。树突状细胞是罕见的白细胞,是一种在发出人体免疫反应信号过程中发挥作用的细胞。树突状细胞在将抗原提供给 T 细胞的能力方面尤其独特。通过激活 T 细胞,树突状细胞有助于促进抗肿瘤反应。这些免疫细胞可以通过抑制肿瘤细胞的生长速度来帮助预防癌症的发病。
树突状细胞疗法的作用原理是分离已加载肿瘤抗原的树突状细胞,并将其用作细胞疫苗。在研究中发现,树突状细胞癌症疗法可以提供治疗性和保护性抗肿瘤免疫,针对患有黑色素瘤和非霍奇金淋巴瘤的癌症患者进行的临床试验显示出积极的抗肿瘤效果。
Administrating DC therapy in a combination therapy with conventional cancer treatments such as chemotherapy and radiotherapy can serve as a promising treatment plan to improve its efficacy.
进行树突状细胞治疗的方法
树突状细胞疗法可以进行静脉注射、肌肉注射、皮内注射或直接肿瘤注射。注射间隔从数天到数月不等。请咨询您的医生,以根据您的个人健康需求确定最佳给药方式、剂量和癌症免疫治疗频率。
还有其他问题吗?立即致电 Immunity Therapy Center 并开启您的康复之旅!
来源:
- “Optimizing Dendritic Cell-Based Approaches for Cancer Immunotherapy” ( Datta, Jashodeep; Terhune, Julia H.; Lowenfeld, Lea; Cintolo, Jessica A.; Xu, Shuwen; Roses, Robert E.; Czerniecki, Brian J.) : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257036/
- “ISOLATION AND GENERATION OF HUMAN DENDRITIC CELLS” by Smita Nair, Thomas Tedder, Gerald E. Archer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559332/
- “Manufacturing Dendritic Cells for Immunotherapy: Monocyte” by : https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(20)30008-5
At Immunity Therapy Center, our goal is to provide objective, updated, and research-based information on all health-related topics. This article is based on scientific research and/or other scientific articles. All information has been fact-checked and reviewed by Dr. Carlos Bautista, a Board Certified Medical Doctor at Immunity Therapy Center. All information published on the site must undergo an extensive review process to ensure accuracy. This article contains trusted sources with all references hyperlinked for the reader's visibility.
量身定制的身心护理
讨论您的其他癌症治疗方案
倾听患者的心声
See why the Immunity Therapy Center is a trusted name for medical tourism and cancer treatment centers in Mexico.